Home
overview
Anti-Inflammatory agents are of paramount importance to the pharmaceutical industry as the process of inflammation covers a wide range of therapeutic areas, such as asthma, arthritis, colitis and allergies. It is important to the industry to ensure that their anti-inflammatory drugs have minimal side effects if they are to succeed in this largely profitable market.

SMi’s conference Anti-Inflammatory Therapeutics aims to address the most recent developments within inflammation, we will focus on target discovery and validation, the clinical trial process, safety and efficacy. In addition to this the conference will cover current drug candidates in the pipeline. This conference will attract attendees from a variety of therapeutic backgrounds where inflammation is a key issue.

A unique opportunity to learn from leading industry experts including:
Dr Claude Bertrand, Director, Research, Pfizer
Dr Martin Braddock, Associate Director, AstraZeneca
Dr Rocco Cirillo, Head, Experimental Pharmacology, Serono
Dr Tim Bourne, Head, Immunopharmacology, Celltech
Gordon Letts, Chief Scientific Officer & Senior Vice President, R&D, NitroMed
Dr Wolfgang Albrecht, Head, Drug Research, Merckle
Dr Sharyn D’Souza, Senior Director, Skeletal Disease & Inflammation, Kendle International
Dr David Stirling, Chief Scientific Officer & Executive Vice President, Research & Development, Celgene

Benefits of Attending:
· NOVEL THERAPIES: Find out about the latest developments and research in inflammation
· IL-1 AND NITRIC OXIDE: Discover the key developments in these areas and the potential they hold for anti-inflammatory therapeutics
· IN VIVO MODELS: Hear about the latest animal research in inflammation
· CLINICAL TRIALS: Understand the complexities of safety and efficacy in this field
· THE FUTURE: Evaluate the molecular targets and therapeutic strategies that will lead to improvements in inflammation

“Very good programme. This one covers a number of topics not presented at the usual inflammation meetings”
Dr John Rediske, Novartis

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Professor Derek Willoughby

Professor Derek Willoughby, Emeritus Professor, William Harvey Research Institute

9:10 INFLAMMATORY MEDIATORS IN HUMAN DISEASE

Dr Terry Plasse

Dr Terry Plasse, Vice President, Research & Development, Cytokine PharmaSciences

  • Traditional inflammatory diseases
  • Other diseases in which inflammatory mediators are involved
  • Similarities in cytokine/mediator profiles
  • Differences in profiles and responsiveness
  • The above points will be illustated by examples with products under development at Cytokine PharmaSciences, as well as examples from the scientific literature
  • 9:40 HEME-OXYGENASE (HSP-32)

    Dr Michel Seed

    Dr Michel Seed, Hon. Senior Lecturer, William Harvey Research Institute, Barts & The London

    Heme-oxygenase (HSP-32) roles and responsibilities

    10:20 LARGE SCALE BIOSIMULATION OF INFLAMMATORY DISEASES

    Christopher McKenna

    Christopher McKenna, Director, Business Development, Immunology & Inflammation, Entelos

    What is biosimulation?

    11:00 Morning Coffee

    11:20 GLUCOCORTICOID SUBSTITUTES

    Dr Cliff Whelen

    Dr Cliff Whelen, , Independent Consultant (formerly University of Hertfordshire and Glaxo)

    Can more selective glucocorticoids be developed?

    12:00 NOVEL ANTI-INFLAMMATORY COMPOUNDS BASED ON THE BIOLOGY OF THALIDOMIDE

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer & Executive Vice President, Pharmaceutical Research & Development, Celgene

    Inhibition of TNFa expression

    12:40 Networking Lunch

    14:00 IL-1 AND ITS ROLE IN INFLAMMATORY DISEASE

    Dr Martin Braddock

    Dr Martin Braddock, Associate Director, AstraZeneca

  • The role of chemokines and cytokines
  • IL-1 in skeletal inflammation and other therapeutic areas
  • How this knowledge can be utilised: therapeutic potential
  • 14:40 INHIBITORS OF INFLAMMATORY CELLS

    Dr Rocco Cirillo

    Dr Rocco Cirillo, Head, Experimental Pharmacology, Serono

  • Inflammatory cells (neutrophils, lymphocytes)
  • Inhibitors of kinases and chemokines as anti-inflammatory agents
  • How this research is shaping drug development
  • 15:20 Afternoon Tea

    15:40 A Novel Approach to old concept

    Maria Sjoberg

    Maria Sjoberg, Project manager, Karo Bio Ab

    Toll-like receptors (TLRs) as key mediators of immune responses

    16:20 ANTI-INFLAMMATORY MONOCLONAL ANTIBODIES

    Dr Tim Bourne

    Dr Tim Bourne, Head, Immunopharmacology, Celltech

  • What makes an anti-inflammatory mAb an effective drug?
  • Structure-activity relationship of mAb
  • Meeting market demands
  • Effects of TNF inhibitors in inflammatory disease
  • Effect of IL-1inhibitors in inflammatory disease
  • Other potential targets
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Gordon Letts

    Dr Gordon Letts, Chief Scientific Officer & Senior Vice President, Research & Development, NitroMed

    9:10 GANGLIOSIDES AS NOVEL TARGETS FOR IMMUNE MODULATION

    Dr Neil Williams

    Dr Neil Williams, Senior Immunologist, University of Bristol & Hunter-Fleming

  • Prevention of inflammatory diseases by the bacterial protein EtxB
  • The mobilisation of T regulatory cells
  • Cellular and biochemical mechanisms
  • Is anti-inflammation of relevance to infectious diseases?
  • 9:40 NEW ANTI-INFLAMMATORY AGENTS FOR AIRWAY DISEASES

    Chris Compton

    Chris Compton, Executive Director Clinical R & D, Pfizer

    Inflammatory processes in asthma and COPD

    10:20 NITRIC OXIDE (NO) BASED ANTI-INFLAMMATORY AGENTS

    Dr Ennio Ongini

    Dr Ennio Ongini, Senior Director, Research, Nicox

  • Nitric oxide (NO) and inflammation
  • The benefits of NO-releasing NSAIDS in neuroinflammation
  • Properties of NO-releasing paracetamol
  • Contribution of NO when released by glucocorticoids
  • 11:00 Morning Coffee

    11:20 COX-2 SELECTIVE CINODS

    Dr Gordon Letts

    Dr Gordon Letts, Chief Scientific Officer & Senior Vice President, Research & Development, NitroMed

  • Analgesics/anti-inflammatory drugs with added functionality of Nitric Oxide (NO)
  • GI sparing, aspirin tolerable
  • Systemic benefits of NO: platelet function, renal function
  • Ulcer healing
  • 12:00 DEVELOPMENT OF NATURAL PRODUCT DERIVED, NOVEL SMALL MOLECULE ORAL INHIBITORS OF NF-kB INDUCING KINASE

    Dr Michael Palladino

    Dr Michael Palladino, Scientific Co-founder & Vice President, Technology Assessment & Development, Nereus Pharmaceuticals

    Natural product diterpenes as sources of anti-inflammatory agents

    12:40 Networking Lunch

    14:00 LIPOSOMAL CARRIERS FOR THE TREATMENT OF INFLAMMATION DISEASES

    Dr Steffen Panzner

    Dr Steffen Panzner, Chief Executive Officer , Novosom

  • Do’s and Don’ts for liposomal drug delivery systems
  • Formulation of liposomal glucocoticoids
  • Treatment of antigen-induced rheumatoid arthritis in rats with liposomal glucocorticoids
  • Liposomal formulations of nucleic acids for the treatment of inflammation diseases - Smartclies® technology
  • 14:40 A HUMAN GENETICS STUDY TO IDENTIFY GPCRs IMPLICATED IN HUMAN INFLAMMATORY DISEASE

    Dr Roy Pettipher

    Dr Roy Pettipher, Director, Therapeutics, Oxagen

    Single nucleotide polymorphisms occur in GPCRs with high frequency and can have a significant impact on receptor function and disease susceptibility

    15:20 Afternoon Tea

    15:40 GCPRS AND INFLAMMATION

    Richard Huckle

    Richard Huckle, Head, Pharmacology, Axovan

    Examples from current and past areas of research

    16:00 SAFETY & EFFICACY

    Dr Sharyn D’Souza

    Dr Sharyn D’Souza, Associate Director, Skeletal Diseases, Kendle

  • Importance of safety in arthritis therapies
  • What are the key safety concerns?
  • Are certain risks acceptable?
  • Can the safety profiles be improved?
  • 16:40 THE FUTURE FOR ANTI-INFLAMMATORY PHARMACEUTICALS

    Dr Wolfgang Albrecht

    Dr Wolfgang Albrecht, Head, Drug Research, Merckle

    Role of inflammation in various diseases

    17:20 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.